Needham, MA – According to filings with the U.S. Securities and Exchange Commission, Verastem is raising $100,000,000.00 in new funding. Sources indicate as part of senior management Chief Financial Officer, Robert Gagnon played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Verastem

Verastem Oncology is a biopharmaceutical company focused on developing medicines to improve survival and quality of life of cancer patients. Our portfolio consists of small molecule kinase inhibitors that inhibit critical signaling pathways, which promote cancer cell survival and tumor growth. Our people are inspired by the strength, tenacity and courage of those battling cancer. Verastem team is anchored by core values of character, urgency, respect, and excellence. We pride ourselves in being an organization committed to diversity and inclusion in order to achieve and sustain excellence. .

To learn more about Verastem, visit http://www.verastem.com/

Contact:
Robert Gagnon, Chief Financial Officer
781-292-4200
rgagnon@verastem.com
https://www.linkedin.com/in/robert-gagnon-70b279/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved